Effectiveness and Tolerability of Eptinezumab

Launched by UNIVERSITY OF FLORENCE · May 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and tolerability of a treatment called eptinezumab for preventing migraines. It aims to help people who experience episodic or chronic migraines, including those with or without aura (a warning sign that can occur before a migraine). The trial is currently recruiting participants aged 18 and older who have been diagnosed with migraines and experience at least eight migraine days each month.

To join the study, participants should have a headache diary that shows their migraine history from the past few months and be willing to follow the study's procedures. However, people who cannot use eptinezumab for medical reasons, have other serious health issues, are pregnant or breastfeeding, or have changed their migraine prevention treatments recently will not be eligible. If you take part in this trial, you can expect to receive eptinezumab and help researchers understand how well it works for preventing migraines.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
• • Good compliance to study procedures;
• • Availability of headache diary at least of the preceding months before enrolment;
• • At least 8 monthly migraine days.
• Exclusion Criteria:
• • Subjects with contraindications for use of eptinezumab;
• • Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
• • medical comorbidities that could interfere with study results;
• • Pregnancy and breastfeeding
• • Changes in preventive treatments in the month before the first administration of eptinezumab